IN2014DN10670A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10670A
IN2014DN10670A IN10670DEN2014A IN2014DN10670A IN 2014DN10670 A IN2014DN10670 A IN 2014DN10670A IN 10670DEN2014 A IN10670DEN2014 A IN 10670DEN2014A IN 2014DN10670 A IN2014DN10670 A IN 2014DN10670A
Authority
IN
India
Prior art keywords
compound
treating
formula
methods
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
I Robert Silverman
Julie F Liu
Adam J Morgan
Bhaumik Pandya
Scott L Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10670(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of IN2014DN10670A publication Critical patent/IN2014DN10670A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IN10670DEN2014 2012-06-15 2013-06-14 IN2014DN10670A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261660428P 2012-06-15 2012-06-15
US201261678795P 2012-08-02 2012-08-02
PCT/US2013/045919 WO2013188783A1 (fr) 2012-06-15 2013-06-14 Dérivés deutérés de ruxolitinib

Publications (1)

Publication Number Publication Date
IN2014DN10670A true IN2014DN10670A (fr) 2015-08-28

Family

ID=48699982

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10670DEN2014 IN2014DN10670A (fr) 2012-06-15 2013-06-14

Country Status (20)

Country Link
US (7) US20150197525A1 (fr)
EP (4) EP2861600A1 (fr)
AU (3) AU2013274030B2 (fr)
BR (1) BR122023027277A2 (fr)
CA (1) CA2876306C (fr)
DK (2) DK3882249T3 (fr)
EA (1) EA201492287A1 (fr)
ES (2) ES2867048T3 (fr)
FI (1) FI3882249T3 (fr)
HR (1) HRP20250965T1 (fr)
HU (1) HUE073180T2 (fr)
IN (1) IN2014DN10670A (fr)
LT (1) LT3882249T (fr)
MX (2) MX360495B (fr)
PL (2) PL3450434T3 (fr)
PT (1) PT3882249T (fr)
RS (1) RS67061B1 (fr)
SI (1) SI3882249T1 (fr)
SM (1) SMT202500302T1 (fr)
WO (1) WO2013188783A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
EP3354652B1 (fr) 2010-03-10 2020-05-06 Incyte Holdings Corporation Dérivés de pipéridine-4-yl azétidine utilisés en tant qu'inhibiteurs de jak1
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
DK3882249T3 (da) 2012-06-15 2025-08-25 Sun Pharmaceutical Ind Inc Deutererede derivater af ruxolitinib
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015184087A2 (fr) 2014-05-28 2015-12-03 Institute For Myeloma & Bone Cancer Research Effets anti-cancéreux d'inhibiteurs de jak2 en combinaison avec des dérivés de thalidomide et des glucocorticoïdes
EP3325479B1 (fr) 2015-06-03 2020-12-02 UWM Research Foundation, Inc. Ligands sélectifs vis-à-vis des récepteurs gabaa contenant une sous-unité alpha 6 et leurs procédés d'utilisation
EP3411031B1 (fr) 2016-02-04 2024-07-24 CinDome Pharma, Inc. Compositions de dompéridone deutérée et méthodes pour la thérapie de troubles
AU2017217806A1 (en) * 2016-02-12 2018-08-16 Vertex Pharmaceuticals (Europe) Limited Deuterium-modified CFTR modulators
LT3452039T (lt) * 2016-05-04 2024-10-25 Sun Pharmaceutical Industries, Inc. Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais
CN110072519A (zh) 2016-12-14 2019-07-30 普罗根尼蒂公司 使用jak抑制剂治疗胃肠道疾病及装置
KR20240125702A (ko) 2017-06-30 2024-08-19 신돔 파마, 인크. 중수소화 돔페리돈 조성물, 방법, 및 제조
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
US20200353419A1 (en) 2017-11-22 2020-11-12 Dauntless 1, Inc. Membrane emulsification device for microsphere creation
EP3713545A1 (fr) 2017-11-22 2020-09-30 Dauntless 1, Inc. Formulations de composé thérapeutique
US11179412B2 (en) * 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3762424A1 (fr) 2018-03-08 2021-01-13 Novartis AG Utilisation d'un anticorps anti-p-sélectine
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
JP7565798B2 (ja) 2018-03-30 2024-10-11 インサイト・コーポレイション 炎症性皮膚疾患のバイオマーカー
MX2020010815A (es) 2018-04-13 2020-12-11 Incyte Corp Biomarcadores para enfermedad de injerto contra hospedero.
WO2020039401A1 (fr) 2018-08-24 2020-02-27 Novartis Ag Traitement comprenant des anticorps se liant à il-1 βeta et ses combinaisons
CA3129096A1 (fr) * 2019-02-06 2020-08-13 Concert Pharmaceuticals, Inc. Procede de preparation d'inhibiteurs de jak enrichis en enantiomeres
PH12021552130A1 (en) 2019-03-05 2022-08-31 Incyte Corp Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
TW202102222A (zh) 2019-03-19 2021-01-16 美商英塞特公司 白斑病之生物標記物
US11731947B2 (en) 2019-04-10 2023-08-22 University Of Notre Dame Du Lac Deuterated antimicrobial compounds
EP3963843A4 (fr) 2019-05-02 2023-01-25 INTEL Corporation Qualité de service (qos) dans un réseautage centré sur l'information (icn)
WO2020236950A1 (fr) 2019-05-21 2020-11-26 Dauntless 1, Inc. Formulations de microsphères thérapeutiques contenant des polymères chargés
JP2022548627A (ja) 2019-09-16 2022-11-21 ノバルティス アーゲー 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
WO2021053489A1 (fr) 2019-09-16 2021-03-25 Novartis Ag Utilisation d'un inhibiteur de mdm2 pour le traitement de la myélofibrose
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4041204A1 (fr) 2019-10-10 2022-08-17 Incyte Corporation Biomarqueurs de la maladie du greffon contre l'hôte
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP7518900B2 (ja) 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
BR112022009710A2 (pt) 2019-11-22 2022-08-09 Incyte Corp Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2021236139A1 (fr) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Nouvel inhibiteur de jak deutéré et ses utilisations
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN116348467A (zh) 2020-08-12 2023-06-27 康塞特医药品有限公司 用于制备对映异构体富集的jak抑制剂的方法
US20240000777A1 (en) 2020-10-08 2024-01-04 Novartis Ag Use of an erk inhibitor for the treatment of myelofibrosis
IL302401A (en) 2020-10-28 2023-06-01 Sun Pharmaceutical Ind Inc Regimens for the treatment of hair loss disorders with faded JAC inhibitors
EP4247383A1 (fr) * 2020-11-19 2023-09-27 Sol-Gel Technologies Ltd. Composition de ruxolitinib ou de ruxolitinib deutéré et ses utilisations
ES3025481T3 (en) 2020-12-04 2025-06-09 Incyte Corp Jak inhibitor with a vitamin d analog for treatment of skin diseases
TW202237083A (zh) 2021-01-11 2022-10-01 美商英塞特公司 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法
CN114853760B (zh) * 2021-02-03 2025-12-05 南京正大天晴制药有限公司 一种芦可替尼中间体的制备方法
CN118159272A (zh) 2021-08-11 2024-06-07 太阳医药工业公司 用氘化的jak抑制剂来治疗脱发病症
EP4384173A1 (fr) 2021-08-12 2024-06-19 Sun Pharmaceutical Industries, Inc. Traitement de troubles sensibles à l'inhibition de jak avec des promédicaments d'inhibiteurs de jak
CN113820413B (zh) * 2021-09-17 2023-04-07 重庆华邦胜凯制药有限公司 高效液相色谱法分离测定磷酸芦可替尼及杂质的方法
EP4518863A1 (fr) 2022-05-04 2025-03-12 Sun Pharmaceutical Industries, Inc. Régimes posologiques pour le traitement avec des inhibiteurs de jak deutérés
CN117384163B (zh) * 2022-07-05 2026-02-17 盛世泰科生物医药技术(苏州)股份有限公司 一种含偕二氟基的化合物及其制备方法和用途
WO2024196761A1 (fr) * 2023-03-17 2024-09-26 Mayo Foundation For Medical Education And Research Utilisation d'inhibiteurs oraux de janus kinase pour traiter le lichen plan
WO2024194352A1 (fr) 2023-03-23 2024-09-26 Glaxosmithkline Intellectual Property (No.3) Limited Modulateurs de p2x3 deutérés
US12364699B2 (en) 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate
US20250325664A1 (en) 2024-04-22 2025-10-23 Incyte Corporation Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor
WO2026020112A1 (fr) * 2024-07-19 2026-01-22 Sun Pharmaceutical Industries, Inc. Formulations orales de deuruxolitinib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
PT1390063E (pt) 2001-05-03 2005-03-31 Hoffmann La Roche Forma de dosagem farmaceutica de mesilato de nelfinavir amorfo
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
CN103214484B (zh) * 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20080103122A1 (en) * 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
HUE029236T2 (en) * 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
WO2009094216A1 (fr) 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Dérivés de géfitinib
PE20211639A1 (es) 2009-01-15 2021-08-24 Incyte Holdings Corp Procesos para preparar inhibidores de jak y compuestos intermediarios relacionado
DK3882249T3 (da) 2012-06-15 2025-08-25 Sun Pharmaceutical Ind Inc Deutererede derivater af ruxolitinib
TWI761825B (zh) * 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型

Also Published As

Publication number Publication date
AU2018271227B2 (en) 2020-08-27
US20150239896A1 (en) 2015-08-27
EP3450434A1 (fr) 2019-03-06
ES3037872T3 (en) 2025-10-07
MX2014015185A (es) 2015-02-17
RS67061B1 (sr) 2025-08-29
US20190308976A1 (en) 2019-10-10
US9249149B2 (en) 2016-02-02
HUE073180T2 (hu) 2026-01-28
PT3882249T (pt) 2025-08-06
PL3450434T3 (pl) 2021-10-04
US20230355629A1 (en) 2023-11-09
DK3450434T3 (da) 2021-05-03
BR112014031204A2 (pt) 2017-06-27
CA2876306C (fr) 2024-02-20
EP3882249A1 (fr) 2021-09-22
FI3882249T3 (fi) 2025-08-11
EA201492287A1 (ru) 2015-07-30
AU2016238877B2 (en) 2018-08-30
SMT202500302T1 (it) 2025-09-12
AU2013274030B2 (en) 2016-07-07
AU2013274030A1 (en) 2015-01-22
BR122023027277A2 (pt) 2024-01-23
LT3882249T (lt) 2025-08-25
PL3882249T3 (pl) 2025-09-08
US20210330674A1 (en) 2021-10-28
MX373123B (es) 2020-04-27
US20250025467A1 (en) 2025-01-23
MX360495B (es) 2018-11-06
SI3882249T1 (sl) 2025-10-30
AU2018271227A1 (en) 2018-12-13
US20170239254A1 (en) 2017-08-24
WO2013188783A8 (fr) 2014-02-27
AU2016238877A1 (en) 2016-10-27
US20150197525A1 (en) 2015-07-16
ES2867048T3 (es) 2021-10-20
EP2861600A1 (fr) 2015-04-22
HRP20250965T1 (hr) 2025-10-10
CA2876306A1 (fr) 2013-12-19
EP4606434A3 (fr) 2025-12-03
WO2013188783A1 (fr) 2013-12-19
DK3882249T3 (da) 2025-08-25
EP3450434B1 (fr) 2021-02-24
EP4606434A2 (fr) 2025-08-27
EP3882249B1 (fr) 2025-05-14

Similar Documents

Publication Publication Date Title
EP4606434A3 (fr) Dérivés deutérés de ruxolitinib
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
IN2015DN01156A (fr)
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
MX2015002040A (es) Baricitinib deuterado.
IN2014MN02598A (fr)
IN2015DN00598A (fr)
MY184303A (en) Notch pathway signaling inhibitor compound
MY199131A (en) Human plasma kallikrein inhibitors
GB201106750D0 (en) Novel compounds
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
IN2014DN06869A (fr)
MX362879B (es) Usos novedosos.
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
IN2014DN07996A (fr)
EA201270728A1 (ru) Пуриновые соединения
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
IN2014DN03010A (fr)
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.